Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study Eudractnummer: 2024-518878-14-01 METcnummer: Protocol ID: NL83071.075.22 / 20221102 Samenvatting Door stijgende kankerincidentie en...
A Phase 3 Randomized, Active-Controlled, Open-label, Multicenter Study to Compare the Efficacy and Safey of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with...
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma...
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma. (KEYNOTE-177) Protocolnummer: 177-00 EudraCT nummer: 2015-002024-89...
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer –...
A randomized phase III study of pembrolizumab given concomitantly to chemoradiation and as maintenance therapy versus chemoradiation alone in patients with locally advanced squamous cell cancer of the...
A multicenter, open label, phase III extension trial to study the long-term safety and efficacy in participants with advanced tumors who are currently on treatment or in follow-up...
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma Protocolnummer:...
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in...
A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab (MK- 3475) Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment...
Een open-label, voor het eerst in mensen, multi-center onderzoek, om de veiligheid, verdraagbaarheid, farmacokinetiek en antitumoractiviteit van een Thorium-227 gelabeld antilichaamchelatorconjugaat, BAY2287411-injectie, te evalueren bij patiënten met solide...
Onderzoek naar de effectiviteit van een multidisciplinaire website voor patiënten met een neuro-endocriene tumor (MultiWeb) Protocolnummer: METc nummer: Samenvatting Het doel van het onderzoek is om...
The Netherlands facility for Cancer-Immune Analysis (N-CIA): studying interaction between immune factors of the tumor and the host Protocolnummer: B18NCI METc nummer: 2019/345 Samenvatting De N-CIA studie is...
Towards improved therapy selection and targeted treatment of nasopharyngeal carcinoma. A proof-of-concept pilot study for somatostatin receptor 2 imaging with [68Ga]Ga-DOTA-TOC PET/CT: the NACASOR trial. Samenvatting Dit is...
Multicenter phase 3 trial comparing NeoADjuvant Ipilimumab + Nivolumab versus standard Adjuvant Nivolumab in macroscopic stage III melanoma – NADINA. Samenvatting Het doel van dit onderzoek is om...
Ovarian cancer treatment with a liposome formulated mRNA Vaccine in combination with (neo-) adjuvant chemotherapy Protocolnummer: OLIVIA-UMCG-01 EudraCT nummer: 2017-004585-10 METc nummer: 2018/689 Samenvatting Het gaat om een...
